Neuraxis announces over $8 million in ib-stim™ revenue

Carmel, ind., aug. 17, 2023 (globe newswire) -- neuraxis, inc. (nyse american: nrxs) (“neuraxis” or the “company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced it has generated over $8 million in revenue following the commercial launch of its proprietary ib-stim™ technology. sales began after neuraxis received fda clearance for ib-stim™ in the pediatric treatment of functional abdominal pain and irritable bowel syndrome. neuraxis is conducting clinical trials with ib-stim™ for four additional pediatric indications, including chronic nausea, post-concussion syndrome, chemotherapy induced nausea and vomiting, and cyclic vomiting syndrome.
NRXS Ratings Summary
NRXS Quant Ranking